152 related articles for article (PubMed ID: 30017171)
1. Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers.
Zuo CZ; Gong Y; Hou XY; Zhang YF; Peng WX; Zhu RH; Zhong DF; Chen XY
Clin Ther; 2018 Aug; 40(8):1347-1356. PubMed ID: 30017171
[TBL] [Abstract][Full Text] [Related]
2. Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects.
Yang L; Shen Q; Hu C; Wang Y; Zhu X; Shu S; Luo Z
Drug Des Devel Ther; 2022; 16():3865-3876. PubMed ID: 36388081
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of imrecoxib in patients with renal insufficiency.
Pei Q; Xie JL; Huang J; Liu WY; Yang XY; Wang Y; Li W; Tan HY; Zhang H; Yang GP
Eur J Clin Pharmacol; 2019 Oct; 75(10):1355-1360. PubMed ID: 31243478
[TBL] [Abstract][Full Text] [Related]
4. Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers.
Youn Choi H; Jin SJ; Jung JA; Kim UJ; Ko YJ; Noh YH; Bae KS; Lim HS
Clin Ther; 2014 Jan; 36(1):115-25. PubMed ID: 24417786
[TBL] [Abstract][Full Text] [Related]
5. Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Liu Y; Zhang R; Li Z; Zhou J; Yang T; Yang C; Huang X; Zhang Y; Shi S
Sci Rep; 2019 Oct; 9(1):15774. PubMed ID: 31673051
[TBL] [Abstract][Full Text] [Related]
6. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and excretion of imrecoxib in rat.
Xu H; Zhang Y; Sun Y; Zhang P; Chu F; Guo Z; Zhang H; Zhong D
Xenobiotica; 2006 May; 36(5):441-55. PubMed ID: 16854781
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous determination of imrecoxib and its two active metabolites in plasma of hepatic impairment patients by liquid chromatography-tandem mass spectrometry.
Hou X; Dai X; Yang Y; Zhang Y; Zhong D; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Aug; 1122-1123():58-63. PubMed ID: 31153132
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
[TBL] [Abstract][Full Text] [Related]
10. Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects.
Scott G; Yih L; Yeh CM; Milosavljev S; Laurent A; Rordorf C
J Clin Pharmacol; 2004 Feb; 44(2):193-9. PubMed ID: 14747429
[TBL] [Abstract][Full Text] [Related]
11. Differences in the In Vivo and In Vitro Metabolism of Imrecoxib in Humans: Formation of the Rate-Limiting Aldehyde Intermediate.
Hou X; Zhou J; Yu S; Zhou L; Zhang Y; Zhong D; Chen X
Drug Metab Dispos; 2018 Sep; 46(9):1320-1328. PubMed ID: 29980580
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
[TBL] [Abstract][Full Text] [Related]
13. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
Gardin A; Ufer M; Legangneux E; Rossato G; Jin Y; Su Z; Pal P; Li W; Shakeri-Nejad K
Clin Pharmacokinet; 2019 Mar; 58(3):349-361. PubMed ID: 30088221
[TBL] [Abstract][Full Text] [Related]
14. Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.
Liu R; Gong C; Tao L; Yang W; Zheng X; Ma P; Ding L
Eur J Pharm Sci; 2015 Nov; 79():13-9. PubMed ID: 26360837
[TBL] [Abstract][Full Text] [Related]
15. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
[TBL] [Abstract][Full Text] [Related]
16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
17. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label pharmacokinetic comparison of two oral formulations of fluconazole 150 mg in healthy adult volunteers.
Jovanović D; Kilibarda V; Cirić B; Vucinić S; Srnić D; Vehabović M; Potogija N
Clin Ther; 2005 Oct; 27(10):1588-95. PubMed ID: 16330294
[TBL] [Abstract][Full Text] [Related]
20. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
Malhotra B; Dickins M; Alvey C; Jumadilova Z; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):263-9. PubMed ID: 21545485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
